Skip to Content


Gordon Mills, M.D., Ph.D., chair of the Department of Systems Biology at MD Anderson, and John Mendelsohn, M.D., Past-President of MD Anderson, are Co-Directors of the Khalifa Institute for Personalized Cancer Therapy.  

Dr. Mendelsohn has been a leader in the field of targeted cancer therapy since 1980, creating, with his colleagues, the first reported inhibitor of the product of a tyrosine kinase oncogene – monoclonal antibody C225 against the EGF receptor – which ultimately led to the FDA approval of the drug, renamed cetuximab (Erbitux), in 2004. 

Dr. Mills’ extensive experience with rapidly evolving technology used in the discovery of biomarkers and their application in clinical trials and patient care, directing the Kleberg Center for Molecular Markers, and his visionary T9 program (Ten Thousand Tumors, Ten Thousand Tests, Ten Thousand Therapies) that screens the 40+ most commonly mutationally activated genes, will ensure a timely transition from research to clinic. He designed the T9 program to identify and overcome the hurdles to the first phase of “delivering on the promise of personalized molecular medicine.” Indeed, the approaches developed for T9 will drive the first phase of the genetic and molecular analysis in the Institute. He is leveraging the innovation and discovery of the Kleberg Center for Molecular Markers with the refinements necessary for implementation of CLIA-compliant assays, required for clinical decisions. 

This approach will allow MD Anderson Cancer Center to lead the country in the rapid and efficient implementation of the next generation of technologies in patient care.

Institute Leadership


John Mendelsohn, M.D.

Director, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy

Gordon Mills, M.D., Ph.D.

Co-Director, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy


Funda Meric-Bernstam, M.D.

Medical Director, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy


Kenna Shaw, Ph.D.

Executive Director, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy


Executive Committee

Gordon Mills, M.D., Ph.D.

John Mendelsohn, M.D.

Funda Meric-Bernstam, M.D.

Kenna Shaw, Ph.D.

Stanley Hamilton, M.D.

Marshall Hicks, M.D.



Ahmed Pancreatic Cancer Center - Anirban Maitra, MBBS

Bioinformatics - John Weinstein, M.D., Ph.D.

Biostatistics - Jack Lee, Ph.D.

Cancer Medicine, Liquid Tumors - Jorge Cortes, M.D.

Cancer Medicine, Solid Tumors - W. K. Alfred Yung, M.D.

Clinical Research Office - Aman Buzdar, M.D.

Duncan Family Institute - Powel Brown, M.D., Ph.D.

Immunology - Patrick Hwu, M.D.

Institute for Cancer Care Excellence - Thomas Feeley, M.D.

Internal Medicine - Robert Gagel, M.D.

Pathology - Ignacio Wistuba, M.D.

Pediatrics - Laurence Cooper, M.D., Ph.D.

Phase I - Robert Wolff, M.D.

Radiation Oncology -Wendy Woodward, M.D. Ph.D.

Surgery - David Gershenon, M.D.

Underserved Populations - Michael Fisch, M.D., PMPH

United Arab Emirates - Robert Wolff, M.D. 


Internal Advisory Board

Kenneth Aldape, M.D., Professor, Department Pathology

Thomas Buchholz, M.D., Provost & EVP Ad Interim, Provost and EVP

Lee Ellis, M.D., Professor of Surgery, Department of Surgical Oncology

Elizabeth Grimm, Ph.D., Deputy Division Head for Research Affairs, Division of Cancer Medicine; Professor, Departments of Experimental Therapeutics and Melanoma Medical Oncology

Waun Ki Hong, M.D., Head, Division of Cancer Medicine; Professor, Thoracic/Head and Neck Medical Oncology

Edward Kim, M.D., Chief, Section of Head and Neck Medical Oncology; Associate Professor, Department of Thoracic/Head and Neck Medical Oncology

Raphael Pollock, M.D., Ph.D., Professor of Surgery, Department of Surgery

Lajos Pusztai, M.D., DPhil, Professor, Breast Medical Oncology

Steven Sherman, M.D., Professor and Chair, Department of Endocrine Neoplasia and Hormonal Disorder

Stephen Swisher, M.D., Professor, Thoracic Surgery


External Advisory Board

Steven Friend, Ph.D., Sage Bionetworks

Sanjiv Sam Gambhir, M.D., Ph.D., Stanford School of Medicine

Joe W. Gray, Ph.D., Oregon Health and Science University

Marc Ladanyi, M.D., Memorial Sloan-Kettering Cancer Center

David Ransohoff, M.D., University of North Carolina Lineberger Comprehensive Cancer Center

Jeffrey Trent, Ph.D., TGen

Jerry Lanchbury, Ph.D., Myriad Genetics, Inc.

© 2014 The University of Texas MD Anderson Cancer Center